We are looking for adolescents age 12-17 who are suffering from Major Depressive Disorder (MDD) to participate in a new Clinical Research Trial.
Purpose: To find out if an investigational drug is safe and to learn if it works for adolescents who have major depressive disorder (MDD).
FOR MORE INFORMATION CONTACT:
Kennedy Krieger Institute 443-923-3850
716 N. Broadway Baltimore, MD 21205
Robert Findling, M.D., M.B.A., Principal Investigator
NA_00086408, clinicaltrials.gov (NCT01878292)
Date: January 13, 2014
If so, please contact us about our 13-week research trial of an investigational, non-medication treatment for depression.
You may be able to participate if:
Qualified participants receive:
To learn more, please visit: http://clinicalconnection.com/PatientViewStudy21720.aspx.
Date: January 10, 2014
Childhood depression and anxiety greatly impact the lives of sufferers, taking away their ability to enjoy their childhood and making them a ghost or shadow of their former selves. We want to change this. We’re conducting ADVANCE – a clinical research study looking at how an investigational treatment called Lu AA21004 is processed in the body over time in children aged 7 to 17 years (inclusively) with depression or anxiety. Study–related treatments and procedures will be provided at no cost to you.
Please contact the study coordinator at 443-923-3850 to learn more.
Principal Investigator: Robert L. Findling, M.D. M.B.A.
Date: September 16, 2013
It may be time to consider your options.
A Clinical Research Study for an investigational medicine is enrolling people who
What is involved?
Compensation for time and travel may be provided
The study doctor can tell you if you meet all the study eligibility requirements.
Sad all the time. No energy. Feeling worthless. Trouble sleeping. Can’t focus. If you are experiencing these symptoms, this study may be right for you.
To learn more and find out if you may qualify, please visit www.DepressionStudies.com http:// www.DepressionStudies.com
Take part in a research study of an investigational medicine at no cost.
To qualify you must be :
For more information contact Premier Psychiatric Research Institute at (402) 476-6060 (Option 4) and www.PremierPsych.com.
Date: March 5, 2013
Most of us have heard of depression, but few people may know about a type of depression that appears along with psychosis (or a loss of touch with reality). Referred to as psychotic major depression (PMD), it’s a surprisingly common mental disorder that affects more than one in 100 individuals. If you or someone in your life has depressed feelings along with ideas or ways of thinking that are not true and/or see or hear things that aren’t there – it may be PMD. With PMD for example, people may hear voices telling them that they don’t deserve to live. There is a high risk of suicide for individuals with PMD so it’s critical to seek help and get treated immediately. [Note: If you have thoughts of suicide or harming yourself or others, immediately call 911 or go to your nearest hospital emergency room. You also may call a confidential suicide hotline from anywhere in the United States, 24 hours a day, seven days a week at 1-800-273-TALK (8255).]
People with PMD can and do get better with treatment. A combination of antidepressant and antipsychotic medication is an effective medication treatment.
In a new study called STOP PD II, researchers are working to understand how long people need to stay on an antipsychotic medication to prevent new episodes of psychosis after recovering from their initial symptoms. Individuals in this study will first receive a combination of an antipsychotic medication and an antidepressant medication for up to 20 weeks. They may begin in an inpatient or outpatient setting. Individuals who are nearly or fully better after up to 20 weeks will be invited to participate in a second phase of the study that lasts for up to 36 weeks.
To be eligible for the study, individuals must be 18 to 85 years old, experiencing symptoms of depression with psychosis, and not be pregnant. Study participants receive medication and medical care at no cost.
For more information about voluntary participation in this study call: Joelle M. Scanlon, PhD, at 412-246-6012
Date: January 24, 2013
Researchers in the Department of Child and Adolescent Studies at Cal State Fullerton are conducting a study to better understand how family members get along when a parent is experiencing some depressive feelings.
Participation includes a phone interview and questionnaires by mail. Families are compensated $25 for their time.
For more information, contact Marian Howland at (657) 278-1088 or email@example.com.
Date: January 8, 2013
The PERT (Perimenopausal Estrogen Replacement Therapy) Study is a clinical research study investigating cardiovascular health and psychological well-being during the menopause transition.
The PERT Study is enrolling two groups of women:
Eligible women will be randomly assigned (i.e., by chance) to either transdermal ERT (a skin patch containing 17b-estradiol) or placebo (a skin patch containing an inert substance). Participants will be involved in the study for 12-13 months with an optional 12 month follow-up period. Approximately 10 visits will be necessary over the initial 12-month period.
You may be eligible to participate if you are:
What will you receive if you participate?
For more information, click here www.pertstudy.com to visit our study website or please call: (919) 972-7495
Date: Nov. 2, 2012
Have you tried medications for your depression in the past which didn’t seem to help?
Are you currently taking an antidepressant but still feel low, tired, and depressed?
The Pursuit study is currently being conducted in your area to determine how safe and effective an investigational medication is for treating MDD.
We are looking for patients who:
The study will last for 20 weeks and will require approximately 20 visits to the study center so that study doctors and nurses can perform various tests and monitor how the drug affects you. Qualified participants will receive all study-related office visits, medical examinations, and investigational medication at no cost. Additionally, the cost of your currently prescribed medications for depression may be supplemented during your study participation.
For more information, click here www.majordepressionstudy.com to visit our study website or please call: 1-888-643-2056
Date: Oct. 6, 2011
The TRIADE trial is designed to assess amitifadine, a new drug being developed as a possible new antidepressant intended to reduce many of the side effects associated with typical antidepressant medications.
Who Can Participate in TRIADE?
What is amitifadine?
What can you expect if you participate in TRIADE?
The trial will be conducted at approximately 30 centers throughout the U.S., and is expected to include approximately 318 individuals.
For full enrollment criteria and to locate a center near you, please call 1 (888) 414-1808 or visit www.trialreach.com/premium/depression.
TRIADE is sponsored by Euthymics® Bioscience, Inc., maker of amitifadine.
Support NAMI to help millions of Americans who face mental illness every day.Donate today
Inspire others with your message of hope. Show others they are not alone.Share your story
Become an advocate. Register on NAMI.org to keep up with NAMI news and events.Join NAMI Today